Caseware UK (AP4) 2024.0.164 2024.0.164 falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.falsetrue2024-07-01No description of principal activity00false 10231985 2025-06-30 10231985 2024-07-01 2025-06-30 10231985 2023-07-01 2024-06-30 10231985 c:Director1 2024-07-01 2025-06-30 10231985 2024-06-30 10231985 c:Director2 2024-07-01 2025-06-30 10231985 d:CurrentFinancialInstruments 2025-06-30 10231985 d:CurrentFinancialInstruments 2024-06-30 10231985 d:CurrentFinancialInstruments d:WithinOneYear 2025-06-30 10231985 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 10231985 d:ShareCapital 2025-06-30 10231985 d:ShareCapital 2024-06-30 10231985 d:RetainedEarningsAccumulatedLosses 2025-06-30 10231985 d:RetainedEarningsAccumulatedLosses 2024-06-30 10231985 c:FRS102 2024-07-01 2025-06-30 10231985 c:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 10231985 c:FullAccounts 2024-07-01 2025-06-30 10231985 c:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 10231985 e:PoundSterling 2024-07-01 2025-06-30 iso4217:GBP xbrli:pure
Company registration number: 10231985











TASA MEDICAL LTD
UNAUDITED
FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
For the Year Ended 30 June 2025

















Coveney Nicholls Limited
Chartered Accountants
The Old Wheel House
31/37 Church Street
Reigate
Surrey
UK
RH2 0AD

 
TASA MEDICAL LTD
Registered number:10231985

BALANCE SHEET
As at 30 June 2025

2025
2024
Note
£
£

  

Current assets
  

Cash at bank and in hand
  
120,719
142,774

  
120,719
142,774

Creditors: amounts falling due within one year
  
(13,386)
(12,116)

Net current assets
  
 
 
107,333
 
 
130,658

Total assets less current liabilities
  
107,333
130,658

  

Net assets
  
107,333
130,658


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
107,233
130,558

  
107,333
130,658


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 15 December 2025.




___________________________
Dr TA Arain
___________________________
Mrs SR Arain
Director
Director

The notes on pages 2 to 4 form part of these financial statements.
Page 1

 
TASA MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

1.


General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is The Old Wheel House, 31-37 Church Street, Reigate, Surrey, RH2 0AD, England.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 2

 
TASA MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

3.


Creditors: Amounts falling due within one year

2025
2024
£
£

Other taxation and social security
714
648

Other creditors
11,072
9,942

Accruals and deferred income
1,600
1,526

13,386
12,116


Page 3

 
TASA MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

4.

Director's advances, credits and guarantees

During the year the directors entered into the following advances and credits with the company:


2025

Balance brought forward and outstanding
Advances/(credits) to the directors
Amounts repaid
Balance outstanding

£
£
£
£

Dr TA Arain
4,971
(500)
1,066
5,537

Mrs SR Arain
4,971
(500)
1,066
5,537

2024

Balance brought forward and outstanding
Advances/(credits) to the directors
Amounts repaid
Balance outstanding

£
£
£
£

Dr TA Arain
4,072
(1,000)
1,899
4,971

Mrs SR Arain
4,072
(1,000)
1,899
4,971


5.


Related party transactions

The company was under the control of Dr TA Arain and Mrs SR Arain throughout the year. Dr and Mrs Arain are the only directors and are equal shareholders. During the year director expenses incurred via the business totalled £1,131 (2024 - £1,797). Dividends of £1,000 (2024 - £2,000) were paid to the directors in the year. At the balance sheet of 30th June 2025, £11,073 (2024 £9,942) was owed to the directors, which is made up of the above. No other transactions were undertaken which would require to be disclosed under FRS 102. 

 
Page 4